Bilastine sales will expand through 2036, with powder at 82.4% of form demand and allergic rhinitis at 68.5% of application sales in 2026. The market is estimated at USD 10.38 million in 2026, is projected to reach USD 22.23 million by 2036 and is forecast to record a 7.9% CAGR between 2026 and 2036.